Chemotherapy and 21-gene recurrence score testing for older breast cancer patients: A competing-risks analysis.

CONCLUSIONS: The competing-risks model is useful in dealing with multiple end events for older breast cancer patients. 21-gene RS was independently associated with BCSM. However, chemotherapy did not significantly decrease the risk of BCSM in intermediate and high RS cohorts. PMID: 33278648 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33278648?dopt=Abstract

Source: Breast - November 28, 2020 Category: Cancer & Oncology Authors: Zhou P, Zhang WW, Bao Y, Wang J, Lian CL, He ZY, Wu SG Tags: Breast Source Type: research